Priming increases the anti-tumor effect and therapeutic window of (177)Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1

BACKGROUND: (177)Lu-[DOTA(0), Tyr(3)]-octreotate ((177)Lu-octreotate) is used for treatment of patients with somatostatin receptor (SSTR) expressing neuroendocrine tumors. However, complete tumor remission is rarely seen, and optimization of treatment protocols is needed. In vitro studies have shown...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:EJNMMI Res
Hlavní autoři: Dalmo, Johanna, Spetz, Johan, Montelius, Mikael, Langen, Britta, Arvidsson, Yvonne, Johansson, Henrik, Parris, Toshima Z., Helou, Khalil, Wängberg, Bo, Nilsson, Ola, Ljungberg, Maria, Forssell-Aronsson, Eva
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2017
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5241264/
https://ncbi.nlm.nih.gov/pubmed/28097640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-016-0247-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky